L
Luigi Camporota
Researcher at Guy's and St Thomas' NHS Foundation Trust
Publications - 213
Citations - 14702
Luigi Camporota is an academic researcher from Guy's and St Thomas' NHS Foundation Trust. The author has contributed to research in topics: Medicine & Extracorporeal membrane oxygenation. The author has an hindex of 27, co-authored 158 publications receiving 10448 citations. Previous affiliations of Luigi Camporota include University of Minnesota & University of Toronto.
Papers
More filters
Journal ArticleDOI
Acute respiratory distress syndrome: the Berlin Definition.
Ards Definition Task Force,V. Marco Ranieri,Gordon D. Rubenfeld,B. Taylor Thompson,Niall D. Ferguson,Ellen Caldwell,Eddy Fan,Luigi Camporota,Luigi Camporota,Arthur S. Slutsky +9 more
TL;DR: The updated and revised Berlin Definition for ARDS addresses a number of the limitations of the AECC definition and may serve as a model to create more accurate, evidence-based, critical illness syndrome definitions and to better inform clinical care, research, and health services planning.
Journal ArticleDOI
COVID-19 pneumonia: different respiratory treatments for different phenotypes?
Luciano Gattinoni,Davide Chiumello,Pietro Caironi,Mattia Busana,Federica Romitti,Luca Brazzi,Luigi Camporota +6 more
TL;DR: It is hypothesize that the different COVID-19 patterns found at presentation in the emergency department depend on the interaction between three factors: the severity of the infection, the host response, physiological reserve and comorbidities; the ventilatory responsiveness of the patient to hypoxemia; and the time elapsed between the onset of the disease and the observation in the hospital.
Journal ArticleDOI
The Berlin definition of ARDS: An expanded rationale, justification, and supplementary material
Niall D. Ferguson,Eddy Fan,Luigi Camporota,Massimo Antonelli,Antonio Anzueto,Richard Beale,Laurent Brochard,Roy G. Brower,Andrés Esteban,Luciano Gattinoni,Andrew Rhodes,Arthur S. Slutsky,Jean Louis Vincent,Gordon D. Rubenfeld,B. Taylor Thompson,V. Marco Ranieri +15 more
TL;DR: This panel addressed some of the limitations of the prior ARDS definition by incorporating current data, physiologic concepts, and clinical trials results to develop the Berlin definition, which should facilitate case recognition and better match treatment options to severity in both research trials and clinical practice.
Journal ArticleDOI
Chest electrical impedance tomography examination, data analysis, terminology, clinical use and recommendations: consensus statement of the TRanslational EIT developmeNt stuDy group
Inéz Frerichs,Marcelo B. P. Amato,Anton H. van Kaam,David G. Tingay,Zhanqi Zhao,Bartłomiej Grychtol,Marc Bodenstein,Hervé Gagnon,Stephan H. Bohm,Eckhard Teschner,Ola Stenqvist,Tommaso Mauri,Vinicius Torsani,Luigi Camporota,Andreas Schibler,Gerhard K. Wolf,Diederik Gommers,Steffen Leonhardt,Andy Adler,Eddy Fan,William R. B. Lionheart,Thomas Riedel,Peter C. Rimensberger,Fernando Suarez Sipmann,Norbert Weiler,Hermann Wrigge +25 more
TL;DR: A new classification of core processes involved in chest EIT examinations and data analysis is provided, and a structured framework to categorise and understand the relationships among analysis approaches and their clinical roles is provided.
Journal ArticleDOI
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial
Carolyn S. Calfee,Kevin L. Delucchi,Pratik Sinha,Michael A. Matthay,Jonathan Hackett,Manu Shankar-Hari,Manu Shankar-Hari,Cliona McDowell,John G Laffey,John G Laffey,John G Laffey,Cecilia O'Kane,Daniel F. McAuley,Andrew Johnston,Archana Paikray,Cat Yates,Petra Polgarova,Esther Price,Amy McInerney,Katarzyna Zamoscik,Ged Dempsey,Colette Seasman,Lynn Gilfeather,Noel Hemmings,Sinead O'Kane,Paul Johnston,Lukas Pokorny,Chris Nutt,Orla O'Neill,Prashast Prashast,Chris Smalley,Reni Jacob,James O'Rourke,Syed Farjad Sultan,Carole Schilling,Gavin D. Perkins,Teresa Melody,Keith Couper,Ron Daniels,Fang Gao,Julian Hull,Timothy Gould,Matthew Thomas,Katie Sweet,Dorothy Breen,Emer Neau,Willis J Peel,Catherine Jardine,Paul Jefferson,Stephen E Wright,Kayla Harris,Sarah Hierons,John G. Laffey,Veronica McInerney,Luigi Camporota,Katie Lei,Sundeep Kaul,Molly Chibvuri,Andrew Gratrix,Rachael Bennett,Victoria Martinson,Lisa Sleight,Neil Smith,Philip Hopkins,Daniel Hadfield,Sarah Casboult,Fiona Wade-Smith,Julie Dawson,Clare Mellis,Clair Harris,Georgina Parsons,Sinead Helyar,Andrew R Bodenham,Stuart Elliot,Zoe Beardow,Sian Birch,Brian Marsh,Teresa Martin,Akesh Dhrampal,Melissa Rosbergen,Stephen T. Webb,Fiona Bottrill,Henrik Reschreiter,Helena Barcraft-Barnes,Julie Camsooksai,Andrew Johnston,Aisling Clarkson,Conor Bentley,Lauren Cooper,Yongyan Qui,Natalie Mitchell,Ronald Carrera,Arlo Whitehouse,Christopher Danbury,Nicola Jacques,Abby Brown,David Rogerson,Craig Morris,Timothy S. Walsh,Mike Gillies,Grant Price,Kallirroi Kefala,Neil Young,David Hope,Corrienne McCulloch,Jean Antonelli,Pam Ramsay,Kirsty Everingham,Louise Boardman,Heidi Dawson,Fiona Pollock,Joanne Thompson,Ingeborg Welters,Lee Poole,Peter Hampshire,Alison Hall,Karen Williams,Anna Walker,Laura Youds,Samantha Hendry,Victoria Waugh,Julie Patrick-Heselton,David Shaw,Irfan Chaudry,Jacqueline Baldwin,Stephen Drage,Laura Ortiz-Ruiz de Gordoa,Daniel McAuley,Leona Bannon,Vanessa Quinn,Lia McNamee,Griania White,Maurizio Cecconi,Johannes Mellinghoff,Donal Ryan,Alistair Nichol,Banwari Agarwal,Paula Meale,Sarah James,Kulwant Dhadwal,Daniel Martin,Agnieszka Walecka,Stephen G. Ward,John Trinder,Samantha Hagan,Janice Montgomery,Catherine Leonard,Elizabeth Lemon,Tom Trinick,Murthy Buddhavarapu,Geraldine Ward,Christopher Bassford,Alan Davidson,Kate McGuigan,Anissa Benchiheub,Naomi Hickey,Alexander Binning,Steven Henderson,J A Wood,Andrew Burtenshaw,Dawn Kelly,Terry Martin,Jessica Thrush,Julie Wollaston,Stephen Graystone,Gavin Nicol,Gareth Sellors +166 more
TL;DR: Although HARP-2 found no difference in 28-day survival between placebo and simvastatin, significantly different survival was identified across patients stratified by treatment and subphenotype (p<0·0001), and within the hyperinflammatory subphenotypes, patients treated with simVastatin had significantly higher 28- day survival than did those given placebo.